PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53

Biochemical and Biophysical Research Communications

Volumn 364, Issue 2, 2007, Pages 344-350

  Zheng, Gang ^a   Ning, Jinying ^a   Yang, Yu Chung ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dimer stability; Pirh2; PLAGL2

Indexed keywords

ONCOPROTEIN; PROTEIN P53; PROTEIN PIRH2; PROTEIN PLAGL2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; DIMERIZATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY;

CELL LINE; DIMERIZATION; DNA-BINDING PROTEINS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 35448998867     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.10.003     Document Type: Article

References (33)

1. Kas K., Voz M.L., Hensen K., Meyen E., and Van de Ven W.J. Transcriptional activation capacity of the novel PLAG family of zinc finger proteins. J. Biol. Chem. 273 (1998) 23026-23032
2. Hibbard M.K., Kozakewich H.P., Dal Cin P., Sciot R., Tan X., Xiao S., and Fletcher J.A. PLAG1 fusion oncogenes in lipoblastoma. Cancer Res. 60 (2000) 4869-4872
3. Gisselsson D., Hibbard M.K., Dal Cin P., Sciot R., Hsi B.L., Kozakewich H.P., and Fletcher J.A. PLAG1 alterations in lipoblastoma: involvement in varied mesenchymal cell types and evidence for alternative oncogenic mechanisms. Am. J. Pathol. 159 (2001) 955-962
4. Astrom A., D'Amore E.S., Sainati L., Panarello C., Morerio C., Mark J., and Stenman G. Evidence of involvement of the PLAG1 gene in lipoblastomas. Int. J. Oncol. 16 (2000) 1107-1110
5. Astrom A.K., Voz M.L., Kas K., Roijer E., Wedell B., Mandahl N., Van de Ven W., Mark J., and Stenman G. Conserved mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: identification of SII as a new fusion partner gene. Cancer Res. 59 (1999) 918-923
6. Castilla L.H., Perrat P., Martinez N.J., Landrette S.F., Keys R., Oikemus S., Flanegan J., Heilman S., Garrett L., Dutra A., Anderson S., Pihan G.A., Wolff L., and Liu P.P. Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 101 (2004) 4924-4929
7. Landrette S.F., Kuo Y.H., Hensen K., Barjesteh van Waalwijk van Doorn-Khosrovani S., Perrat P.N., Van de Ven W.J., Delwel R., and Castilla L.H. Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11. Blood 105 (2005) 2900-2907
8. Hensen K., Van Valckenborgh I.C., Kas K., Van de Ven W.J., and Voz M.L. The tumorigenic diversity of the three PLAG family members is associated with different DNA binding capacities. Cancer Res. 62 (2002) 1510-1517
9. phox expression and NADPH oxidase activity. J. Biol. Chem. 282 (2007) 17941-17952
10. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
11. Lowe S.W., and Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13 (2003) 77-83
12. Brooks C.L., and Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15 (2003) 164-171
13. Pomerantz J., Schreiber-Agus N., Liegeois N.J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.W., Cordon-Cardo C., and DePinho R.A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92 (1998) 713-723
14. Zhang Y., Wolf G.W., Bhat K., Jin A., Allio T., Burkhart W.A., and Xiong Y. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 23 (2003) 8902-8912
15. Li L., Liao J., Ruland J., Mak T.W., and Cohen S.N. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc. Natl. Acad. Sci. USA 98 (2001) 1619-1624
16. Brady M., Vlatkovic N., and Boyd M.T. Regulation of p53 and MDM2 activity by MTBP. Mol. Cell. Biol. 25 (2005) 545-553
17. Sui G., Affar el B., Shi Y., Brignone C., Wall N.R., Yin P., Donohoe M., Luke M.P., Calvo D., and Grossman S.R. Yin Yang 1 is a negative regulator of p53. Cell 117 (2004) 859-872
18. Maya R., Balass M., Kim S.T., Shkedy D., Leal J.F., Shifman O., Moas M., Buschmann T., Ronai Z., Shiloh Y., Kastan M.B., Katzir E., and Oren M. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15 (2001) 1067-1077
19. Scheffner M., Huibregtse J.M., Vierstra R.D., and Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75 (1993) 495-505
20. Dornan D., Wertz I., Shimizu H., Arnott D., Frantz G.D., Dowd P., O'Rourke K., Koeppen H., and Dixit V.M. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429 (2004) 86-92
21. Chen D., Kon N., Li M., Zhang W., Qin J., and Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121 (2005) 1071-1083
22. Leng R.P., Lin Y., Ma W., Wu H., Lemmers B., Chung S., Parant J.M., Lozano G., Hakem R., and Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112 (2003) 779-791
23. Liu J., Zhu Y., Chen I., Lau J., He F., Lau A., Wang Z., Karuppannan A.K., and Kwang J. The ORF3 protein of porcine circovirus type 2 interacts with porcine ubiquitin E3 ligase Pirh2 and facilitates p53 expression in viral infection. J. Virol. 81 (2007) 9560-9567
24. Logan I.R., Sapountzi V., Gaughan L., Neal D.E., and Robson C.N. Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome. J. Biol. Chem. 279 (2004) 11696-11704
25. Nikolay R., Wiederkehr T., Rist W., Kramer G., Mayer M.P., and Bukau B. Dimerization of the human E3 ligase CHIP via a coiled-coil domain is essential for its activity. J. Biol. Chem. 279 (2004) 2673-2678
26. Ravi K., Brennan L.A., Levic S., Ross P.A., and Black S.M. S-nitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity. Proc. Natl. Acad. Sci. USA 101 (2004) 2619-2624
27. Johnson P.R., Swanson R., Rakhilina L., and Hochstrasser M. Degradation signal masking by heterodimerization of MATalpha2 and MATa1 blocks their mutual destruction by the ubiquitin-proteasome pathway. Cell 94 (1998) 217-227
28. Bender A.T., Demady D.R., and Osawa Y. Ubiquitination of neuronal nitric-oxide synthase in vitro and in vivo. J. Biol. Chem. 275 (2000) 17407-17411
29. Hattori T., Ohoka N., Inoue Y., Hayashi H., and Onozaki K. C/EBP family transcription factors are degraded by the proteasome but stabilized by forming dimer. Oncogene 22 (2003) 1273-1280
30. Abu-Soud H.M., Wang J., Rousseau D.L., Fukuto J.M., Ignarro L.J., and Stuehr D.J. Neuronal nitric oxide synthase self-inactivates by forming a ferrous-nitrosyl complex during aerobic catalysis. J. Biol. Chem. 270 (1995) 22997-23006
31. Albakri Q.A., and Stuehr D.J. Intracellular assembly of inducible NO synthase is limited by nitric oxide-mediated changes in heme insertion and availability. J. Biol. Chem. 271 (1996) 5414-5421
32. Ratovitski E.A., Bao C., Quick R.A., McMillan A., Kozlovsky C., and Lowenstein C.J. An inducible nitric-oxide synthase (NOS)-associated protein inhibits NOS dimerization and activity. J. Biol. Chem. 274 (1999) 30250-30257
33. Duan W., Gao L., Druhan L.J., Zhu W.G., Morrison C., Otterson G.A., and Villalona-Calero M.A. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J. Natl. Cancer Inst. 96 (2004) 1718-1721